Panacea Biotec Limited has reported a fire incident at the Oncology Quality Control Laboratory of its wholly owned subsidiary, Panacea Biotec Pharma Limited (PBPL), located in Baddi, Himachal Pradesh. The incident occurred on April 30, 2026, temporarily disrupting operations at the facility.

Incident Details

The fire broke out on Thursday, April 30, 2026, at approximately 12:23 P.M. due to a short circuit at the Oncology Quality Control Laboratory. The company's internal team successfully controlled the fire within a short timeframe, preventing any escalation of the situation.

Operational Impact

The fire incident has resulted in temporary disruption of operations at the Oncology Facility of PBPL. The company estimates that operations will be affected for a period of 5 to 7 days. Despite the operational disruption, Panacea Biotec has indicated that the incident is not likely to have a material impact on the company's financials.

Insurance Coverage and Recovery Measures

PBPL has confirmed that there is adequate insurance coverage for the affected facility. The company has already made the necessary intimation to the insurance company regarding the incident. PBPL is currently assessing the extent of loss and damage resulting from the fire while taking all necessary and adequate measures to restore operations at the earliest possible time.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided all requisite details as required under the regulations, ensuring full transparency with stakeholders and regulatory authorities about the incident and its potential implications.

Panacea Biotec Limited has submitted a regulatory compliance filing to stock exchanges regarding the newspaper publication of a notice for opening a special window for transfer and dematerialization of physical shares. The filing demonstrates the company's adherence to SEBI regulatory requirements for shareholder communication.

Regulatory Compliance Details

The compliance filing was submitted under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice was published on April 15, 2026, following SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026.

Publication Details

The notice regarding the special window for transfer and dematerialization of physical shares was published in two newspapers to ensure wide reach among shareholders:

• Financial Express (English daily)
• Desh Sewak (Punjabi daily)

This dual-language publication approach ensures compliance with regulatory requirements while reaching shareholders across different linguistic preferences.

Stock Exchange Communication

The filing was simultaneously submitted to both major Indian stock exchanges where Panacea Biotec shares are listed:

The communication was signed by Ankit Jain, General Manager- Legal & Company Secretary, and digitally signed on April 15, 2026, at 14:36:05 +05'30'.

Special Window Purpose

The special window initiative is designed to facilitate shareholders holding physical share certificates in transferring and dematerializing their holdings. This process helps shareholders convert their physical certificates into electronic form, making trading and transfer processes more efficient and secure.

The regulatory filing ensures transparency and keeps all stakeholders informed about the company's compliance with SEBI guidelines regarding shareholder services and communication requirements.